Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas


  • The Editors are satisfied that all authors have contributed significantly to this publication



The aim was to assess the clinical relevance of the World Health Organization and tumour node metastasis (TNM) classifications in patients with pancreatic neuroendocrine tumours (pNETs).


Prospectively collected data from 118 consecutive patients with a pNET receiving surgical intervention were analysed.


Forty-one patients had well differentiated neuroendocrine tumours, 64 had well differentiated neuroendocrine carcinomas and 13 had poorly differentiated neuroendocrine carcinomas. Five-year survival rates were 95, 44 and 0 per cent respectively (P < 0·001). There was no difference in survival after R0 and R1/R2 resections in patients with neuroendocrine carcinomas (P = 0·905). In those with well differentiated neuroendocrine carcinomas, any resection and having a clinically non-functional tumour significantly increased survival (P = 0·003 and P = 0·037 respectively). The TNM stage was I in 37 patients, II in 15 patients, III in 32 patients and IV in 34 patients. There were significant differences in 5-year survival between stage I and II (88 and 85 per cent respectively) and stage III and IV (31 and 42 per cent respectively) (P = 0·010).


Both classifications accurately reflect the clinical outcome of patients with pNET. The resection status may not be critical for long-term survival in patients with pNET. Copyright © 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.